Document:

<PAGE>

                                                                 Exhibit 10.21.1

                        Phibro Animal Health Corporation
                                One Parker Plaza
                           Fort, Lee, New Jersey 07024

                      Philipp Brothers Holding Brasil Ltda.
                     Phibro Sa de Animal Internacional Ltda.
                  Avenida Presidente Tancredo de Almeida Neves
                          Guarulhos, Sao Paulo, Brazil

August 11, 2003

Pfizer Inc.
150 East. 42nd Street
New York, New York 10017

Attention:  Pedro Lichtinger

      Re:   Modification to Asset Purchase Agreement,
            Pfizer Supply and Tolling Agreement and Related Documents

Gentlemen:

      Reference is made to (i) the Asset Purchase Agreement, dated as of
September 28, 2000 (the "Asset Purchase Agreement"; capitalized terms used and
not otherwise defined herein shall have the respective meanings attributed
thereto in the Asset Purchase Agreement), among Pfizer Inc. ("Pfizer"), the
Asset Selling Corporations named therein and Phibro Animal Health Corporation
(f/k/a Philipp Brothers Chemicals, Inc.) ("Philipp"), (ii) the Pfizer Supply and
Tolling Agreement, (iii) the Amended and Restated Promissory Note, dated
December 1, 2000 and Amended and Restated as of October 18, 2001 (the "Note")
made by Philipp payable to the order of Pfizer for the principal amount of
$25,093,226 and (iv) the Amendment to Asset Purchase Agreement and Pfizer Supply
and Tolling Agreement, dated October 2000 (the "Letter Amendment"), among the
parties hereto. The Asset Purchase Agreement, the Pfizer Supply and Tolling
Agreement, the Note and the Letter Amendment are collectively referred to here
as the "Purchase Documents".

      As a result of certain business and economic conditions, Philipp is
attempting to restructure its outstanding indebtedness (the "Restructuring"). In
order to facilitate a Restructuring, Philipp has requested that Pfizer, each
Asset Selling Corporation and Laboratorios Pfizer do Brazil Ltda. (collectively,
the "Pfizer Entities") agree to accept the Restructuring
<PAGE>
Pfizer, Inc.                        Page 2                       August 11, 2003

      Consideration (as defined below) in full satisfaction of the Terminating
Obligations (as defined below) if Philipp consummates a Restructuring, and the
Pfizer Entities have agreed to do so, on the terms and subject to the conditions
set forth herein.

      It is hereby agreed as follows;

            1. Terminating Obligations. Subject to the satisfaction of the
conditions precedent set forth in Paragraph 4 below, effective as of the
Effective Date (as defined below):

            (a) All obligations of Philipp and its subsidiaries (collectively,
the "Philipp Entities") under the Note and the Collateral Documents (as defined
in the Note) (approximately $22.6 million as of October 18, 2002 less all
principal payments made after such date) shall be deemed paid and satisfied in
full and all liens and security interests created by the Collateral Documents
shall be terminated and released, and (i) Pfizer shall promptly following the
Effective Date return the original of the Note to Philipp marked "paid in full"
and (ii) the Pfizer Entities shall promptly take all such other action as
Philipp may reasonably request from time to time to evidence the payment and
satisfaction of such obligations and the termination and release of such liens
and security interests;

            (b) All obligations of the Philipp Entities with respect to the Net
Revenue Obligations set forth in paragraph 1 of the Letter Amendment
(approximately $8.6 million as of October 18, 2002 less all payments made after
such date) shall be deemed paid full;

            (e) All obligations of the Philipp Entities under Section 2.6 of the
Asset Purchase Agreement shall terminate and be of no further force or effect;

            (d) All obligations of the Philipp Entities under Section 2.8 of the
Asset Purchase Agreement shall terminated and be of no further force or effect;

            (c) The following sentence set forth in paragraph 1 of the Letter
Amendment shall be deleted in its entirety:

            "From and after March 1, 2004, net revenue payments will accrue and
            become payable in accordance with the terms of the Asset Purchase
            Agreement, with the first such payment (in respect of net revenue
            payments accrued during the period commencing March 1, 2004 and
            ending May 31, 2004) due July 15, 2004."

            (f) All obligations of the Philipp Entities with respect to the
payment for Belgium Virginiamycin inventory set forth in paragraph 2.C. of the
Letter Amendment (approximately $7.6 million as of October 18, 2002 less all
payments made after such date shall be deemed paid and satisfied in full;
<PAGE>
Pfizer, Inc.                        Page 3                       August 11, 2003

            (g) All obligations of the Philipp Entities with respect to payments
for the Rixensart variances set forth in paragraph 2.D. of the Letter Amendment
(approximately $2,618,820 as of October 18, 2002 less all payments made after
such date) shall be deemed paid and satisfied in full;

            (h) All obligations of the Philipp Entities with respect to the
unpaid invoices (approximately $4.5 million as of October 18, 2002 less all
payments made after such date) relating to Bulk Actives manufactured at the
sites in Terre Haute, IN-USA and Sandwich, UK and to Mecadox(R) produced at the
Mecadox(R) facility at Lee*s Summit, MO-USA and shipped by Pfizer prior to
February 1, 2002 (the "Initial Unpaid Invoices") shall be deemed paid and
satisfied in full; and

            (i) Paragraph 2.B.d. of the Letter Amendment shall be amended as
follows:

                  (i) each reference to "Unpaid Invoices" in such paragraph
            shall exclude the Initial Unpaid Invoices; and

                  (ii) the Company shall continue to pay for Affected Products
            on a monthly basis when sold or used in accordance with the terms of
            such paragraph; and

                  (iii) the penultimate sentence of paragraph 2.B.d. shall be
            amended to read in its entirety as follows:

            "All amounts due and owing to Pfizer with respect to Affected
            Products that remain outstanding on December 31, 2007 by reason of
            Philipp not having sold or used the Affected Products prior to such
            date (regardless of the reason for Philipp*s failure to sell or use
            such Affected Products (whether it be expiration, inability to sell
            or otherwise)) shall be due and payable on such December 31, 2007."

The obligations of the Philipp Entities to be paid, satisfied and terminated
pursuant to this Paragraph 1 and the amendments to the Letter Amendment pursuant
to this Paragraph 1 are referred to collectively herein as the "Terminating
Obligations".

            2. Continuation of installment Payments Pending the Philipp Payment.
Notwithstanding anything to the contrary set forth herein, until the Philipp
Payment (as defined in paragraph 4.a. hereof) is made and received by Pfizer,
the Philipp Entities shall continue to be obligated to make all (a) principal
and interest payments due and owing on the Note on the due dates and in
accordance with the terms of the Note and (b) all other payments relating to the
obligations referenced in subparagraphs 1(f), 1(g) and 1(h) when due in
accordance with the terms of the Letter Amendment. In the event the Philipp
Entities fail to make a payment
<PAGE>
Pfizer, Inc.                        Page 4                       August 11, 2003

referenced in clause (a) or (b) of this paragraph 2 when due, then, unless such
amount, together with interest (x) the case of any overdue payment under the
Note, as provided in the Note and (y) in the case of all other payments
referenced in subparagraph 1(f), 1(g) and 1(h), accruing at an annual rate of 7%
from the due date through and including the day prior to payment, is paid by the
Philipp Entities prior to the time of the making of the Philipp Payment, the
amount of the Philipp Payment shall be increased by the amount of any such
missed payment together with interest on such missed payment (x) in the case of
any overdue payment under the Note, as provided in the Note and (y) in the case
of all other payments referenced in subparagraph 1(f), 1(g) and 1(h), accruing
at an annual rate of 7% from the due date through and including the day prior to
the date of the Philipp Payment.

            3. Philipp Payments. Subject to the satisfaction of the conditions
precedent set forth in Paragraph 4 below, effective as of the Effective Date,
none of the Philipp Entities will have any obligations to make payments to any
of the Pfizer Entities, other than payment with respect to the Affected Products
(as defined in the Letter Amendment) in accordance with the terms of the Letter
Amendment (as amended by this letter agreement).

            4. Conditions Precedent. Paragraphs 1 and 3 of this letter agreement
shall become effective if, on or before December 31, 2003, each of the following
conditions shall be satisfied:

            (a) Pfizer shall have received, by wire transfer of immediately
available federal funds to an account designated by Pfizer, the amount of
$28,300,000 increased by (i) any amounts as referenced in the last sentence of
Paragraph 2 and (ii) without duplication of amounts described in clause (i), all
accrued and unpaid interest on the Note through and including the date of the
payment (the `Philipp Payment") from Philipp.

            (b) Pfizer shall have received a letter from Philipp substantially
in the form of Exhibit A hereto confirming the following:

            (i) all of the Pfizer Obligations (as defined in the Letter
      Amendment and relating to the reimbursement of severance payments made by
      the Philipp Entities to U.S. assumed employees and other amounts owed by
      Pfizer Brazil to Philipp Brazil) (approximately $3.7 million) have been
      deemed paid and satisfied in full;

            (ii) all obligations of Pfizer under Section 7.21 of the Asset
      Purchase Agreement and Schedule 7.21 thereto (relating to Pfizer*s
      obligation to share a portion of the net costs of a Rixensart Shutdown
      Event) have been terminated and are of no further force or effect; and

            (iii) Philipp*s representation and warranty to the effect that the
      making of the Philipp Payment has been duly authorized by all necessary
<PAGE>
Pfizer, Inc.                        Page 5                       August 11, 2003

      corporate action and such payment does not (i) require the consent of any
      third party that has not been obtained and (ii) conflict with, constitute
      a breach of or otherwise violate any agreement or other instrument to
      which any of the Philipp Entities is a party.

            The first date that all of the conditions set forth in this
Paragraph 4 are satisfied is referred to herein as the "Effective Date". The
payment by Philipp of the Philipp Payment and the payment, satisfaction and
termination of the obligations of Pfizer pursuant to this Paragraph 4 are
referred to collectively herein as the "Restructuring Consideration".

            5. Termination of Non-Compete Provision. In consideration of
Pfizer*s execution of this letter agreement, Philipp, on behalf of itself and
the other Philipp Entities, hereby agrees that, effective with the execution of
this letter agreement, all obligations of Pfizer under Section 7.6(a) of the
Asset Purchase Agreement relating to Pfizer's non competition obligations are
terminated and are of no further force or effect from and after the date hereof
Accordingly, from and after the date hereof, Sections 7.6(a)-(e) of the Asset
Purchase Agreement hereby are deleted.

            6. Certain Agreements. Pfizer agrees for itself and its Affiliates
(but only for as long as such Affiliates remain Affiliates of Pfizer) that, for
a period of three (3) years from the date hereof, Pfizer and its Affiliates will
not distribute or sell or promote the distribution and sale of any product (a
"Restricted Product") that is competitive with the Phibro products that have
virginiamycin, salinomycin, carbadox, oxytetracyclines or semduramycin as an
active ingredient. Such prohibition shall include the sale by Pfizer or its
Affiliates of any active ingredient to any third party who, to the knowledge of
Pfizer and its Affiliates, is purchasing such active ingredient for the purpose
of the manufacture, distribution or sale of a Restricted Product.

            7. No Other Changes. Except as expressly provided herein, and except
as provided in that certain "First Amendment to the Agreement for Assignment and
Transfer of Establishment in Payment for Capital Stock and Other Covenants"
executed or to be executed by Laboratorios Pfizer Ltda.*[If Agreed] and Phibro
Sa de Animal Internacional Ltda. simultaneously with or following the execution
of this letter agreement, no term or provision of the Purchase Documents shall
be amended, modified or supplemented, and each term and provision of the
Purchase Documents is hereby ratified and shall remain in full force and effect.

            8. Effect of a Bankruptcy Filing on this Letter Agreement. In the
event that at any time prior to the making of the Philipp Payment (a) any of the
Philipp Entities shall file a petition seeking relief under title 11 of the
United States Code or (b) a case or proceeding is commenced against any of the
Philipp Entities seeking a decree or order against any such Philipp Entity under
title 11 of the United States Code and such case or proceeding remains
undismissed or unstayed for thirty consecutive days or a court enters a decree
or order granting the relief sought in such case or proceeding, then the terms
of this letter agreement automatically shall be void arid have no further force
or effect, including, without limitation, the provisions relating to
<PAGE>
Pfizer, Inc.                        Page 6                       August 11, 2003

            the termination and release of the liens and security interests
      created by the Collateral Documents.

            9. Counterparts. This letter agreement may be executed by the
parties hereto in any number of separate counterparts (including by telecopier),
and all of said counterparts taken together shall be deemed to constitute the
same instrument.

If you agree to the foregoing terms and provisions, please evidence your
acceptance by signing and returning to us the enclosed copy of this letter
agreement, whereupon this letter agreement shall become a valid and legally
binding agreement between us.

                                        Very truly yours,

                                        PHIBRO ANIMAL HEALTH CORPORATION

                                        By:  /s/
                                             -----------------------------------
                                              Name:
                                              Title:
<PAGE>
Pfizer, Inc.                        Page 7                       August 11, 2003

                                         PHILIPP BROTHERS HOLDINGS BRAZIL LTDA.

                                         By: /s/
                                             -----------------------------------
                                         Name:
                                         Title:

                                         PHIBRO SAUDE ANIMAL INTERNACIONAL LTDA.

                                         By: /s/
                                             -----------------------------------
                                         Name:
                                         Title:

ACCEPTED AND AGREED
as of August   ,  2003

PFIZER INC. (on its own behalf,
on the behalf of each Asset Selling Corporation
and on behalf of Laboratorios Pfizer do Brazil Ltda.)

By: /s/
    ----------------------------
Name:
Title:<PAGE>

                                                                   EXHIBIT 10.29

                              EMPLOYMENT AGREEMENT

AGREEMENT dated as of May 2, 2003 (the "Agreement`'), by and between PAH
Management Company Ltd., an English corporation (the "Company'`) and David
McBeath, a financial and management Executive (the "Executive'`), residing at
Carwinshoch, Carrick Hills, Ayr KA7 4LD, Scotland.

1.   Engagement. The Company agrees to engage the Executive and the Executive
     agrees to serve the Company as its President. The Executive shall also act
     as President of the Phibro Animal Health Group ("Group") of which the
     Company is a part. The Executive shall report to the Chief Executive
     Officer ("CEO") of Philipp Brothers Chemicals, Inc. ("PBCI"). The Executive
     shall not be required to serve as a member of the Company's Board of
     Directors.

2.   Term. The term of this Agreement shall commence on August 1, 2003
     ("Commencement Date") and shall continue until October 31, 2004.

3.   Services. The Executive shall exert his best efforts and devote
     substantially all of his time and attention to the Group`s affairs. The
     Executive shall be in complete charge of the operation of the Group, and
     shall have full authority and responsibility, subject to the general
     direction, approval, and control of the CEO of PBCI and the Boards of
     Directors of PBCI and the Company, for formulating policies and
     administering the Group in all respects. His powers shall include the
     authority to hire and fire Group personnel and to retain executives, with
     the consent of the CEO, when he deems necessary to implement Group
     policies. The Executive and the CEO of PBCI shall mutually agree on a
     written statement of goals and objectives for the Executive.

4.   Compensation. The Company shall pay the Executive for his services an
     annual compensation of US $250,000.00, to be paid semi-monthly plus
     standard PBCI employee benefits except as provided below. The Executive
     shall be entitled to three (3) weeks vacation for each twelve (12) months
     of employment. In lieu of participation in the Philipp Brothers Chemicals,
     Inc. Management Incentive Program, the Executive shall also be paid US
     $100,000.00 upon the Commencement Date of this Agreement and an additional
     US $130,000.00 ("Completion Fee") upon completion of the full term of this
     Agreement or as such term may be extended.

5.   Expenses. Executive shall be reimbursed for all reasonable out of pocket
     expenses and business class travel, evidenced by a written receipt,
     incurred in connection with the performance of services under this
     Agreement, provided, that all travel, hotel, rental car and other
     transportation related arrangements should be in compliance with the PBCI's
     Travel and Business and Entertainment policies. When in New Jersey on Group
     business the Executive shall be provided with an "Executive" class vehicle
     in accordance with PBCI policies and reimbursement for reasonable housing
     in an amount to be mutually agreed upon.

6.   Taxes. The Executive acknowledges and agrees that personal income and other
     taxes shall be the sole responsibility of the Executive. The Company agrees
     that it will make the Executive whole in the event Executive is subject to
     double taxation or any taxes in addition to those the Executive would have
     paid in his country of residence.

7.   Covenant Not to Compete. Except as provided on Exhibit A hereto, during the
     term of this Agreement, Executive shall not directly or indirectly, either
     for his own account, or as a partner, shareholder, officer, director,
     employee, agent or otherwise; own, manage, operate, control, be employed
     by, participate in, consult with, perform services for, or otherwise be
     connected with any business the same as or similar to the business
     conducted by the Group. In the event any of the provisions of this Section
     7 are determined to be invalid by reason of their scope or duration, this
     Section 7 shall be deemed modified to the extent required to cure the
     invalidity. In the event of a breach, or a threatened breach, of this
     Section 7, Company shall be entitled to obtain an injunction restraining
     the commitments or continuance of the breach, as well as any other legal or
     equitable remedies permitted by law.

                                       1
<PAGE>
8.   Intellectual Property. Executive hereby assigns any and all rights, title
     and interest, including, but not limited to, patents, copyrights,
     tradesecrets and any and all proprietary rights to any inventions,
     processes, creations, plans, programs, or any other material developed in
     the course of performance of services pursuant to this Agreement. All work
     performed hereunder and any and all materials, products, inventions,
     processes, creations, plans, programs or any other material developed or
     produced in the course of performance of service pursuant to this Agreement
     shall be the property of the Company and all title and interest therein
     shall vest in the Company. All such materials which would qualify for
     copyright protection under US copyright laws shall be deemed to be "works
     made for hire" under such copyright laws. Both parties acknowledge and
     agree, however, that Executive shall retain the right to use its knowledge,
     experience, expertise and know-how for other projects for other clients
     notwithstanding the provisions of this Agreement. Executive agrees to give
     the Company such assistance, at the Company's expense, as may be required
     to perfect any assignment of rights described in this Section 8.

9.   Publications. Executive agrees that any proposed publication written or
     prepared by Executive as part of Executive's services under the Agreement
     or that relates to the work performed hereunder must be reviewed and
     approved in writing by the Company prior to submission for publication.

10.  Confidentiality. As part of the performance of services hereunder, the
     Company may disclose to Executive certain Confidential Information.
     "Confidential Information" for the purposes of this Agreement shall include
     Company's proprietary and confidential information such as, but not limited
     to, customer lists, business plans, marketing plans, financial information,
     designs, drawings, specifications, models, software, source codes and
     object codes.

     During the term of this Agreement, and thereafter for a period of five (5)
     years, Executive shall not, except as provided herein, without the prior
     written consent of Company, disclose to anyone any Confidential
     Information.

     The Confidential Information will be kept confidential by Executive and
     will not be used in any way detrimental to Company. The Confidential
     Information will not be used other than in connection with the services
     provided hereunder.

     This Agreement will be inoperative as to such portions of the Confidential
     Information which (i) are or become generally available to the public
     through no fault or action by Executive, (ii) are or become available to
     Executive on a nonconfidential basis from a source, other than Company,
     provided that such source is not prohibited from disclosing such portions
     to Executive by a contractual, legal or fiduciary obligation to Company,
     (iii) was in possession of Executive prior to its disclosure hereunder, or
     (iv) has been or is independently acquired or developed by Executive
     without violating any of the Executive's obligations under this Agreement
     and without the use of any Confidential Information.

     Company acknowledges that Executive may have confidential information from
     other persons or entities and Executive shall not be required nor expected
     to reveal or utilize such confidential information in the performance of
     the services hereunder.

11.  Termination. This Agreement may be terminated by either party, for any
     reason, upon thirty (30) days written notice to the other party.

     A.   This Agreement may be terminated by Company:

          i.   Without notice, if Executive is unable to provide the consulting
               services by reason of temporary or permanent illness, disability,
               incapacity or death.

          ii.  Without notice upon breach or default of any obligation of
               Executive pursuant to Section 7, Covenant Not to Compete, or
               Section 10, Confidentiality, of this Agreement.

          iii. Upon breach or default by Executive of any other material
               obligation in this Agreement, which breach or default is not
               cured within five (5) days of written notice from Company.

          iv.  Without notice for misfeasance or malfeasance by the Executive.

                                       2
<PAGE>
     B.   Executive may terminate this Agreement:

          i.   Upon breach or default of any material obligation of Company,
               which breach or default is not cured within five (5) days of
               written notice from Executive.

          ii.  Without notice, if Company files protection under the federal
               bankruptcy laws, or any bankruptcy petition or petition for
               receiver is commenced by a third party against Company, any of
               the foregoing of which remains undismissed for a period of sixty
               (60) days.

12.  Assignment. Neither party shall assign or delegate this Agreement or any
     rights, duties or obligations hereunder to any other person and/or entity
     without prior express written approval to the other. Subject to the
     foregoing, this Agreement shall inure to the benefit of and be binding upon
     the successors, legal representatives and assignees of the parties hereto.

13.  Payment upon termination. If (i) Executive dies during the term of this
     Agreement; (ii) if this Agreement is terminated under Paragraph 10 because
     of the Executive`s disability; or (iii) this Agreement terminated for
     reasons other than for cause, the Executive or his estate shall be paid, as
     additional compensation hereunder, and in lieu of severance, within 45 days
     after such termination, the Completion Fee less an amount equal to the
     prorated portion of the Completion Fee for the number of months remaining
     under this Agreement.

14.  Indemnity. The Company shall indemnify the Executive and hold him harmless
     for all acts or decisions made by him in good faith while performing
     services for the Company. The Company shall also use its best efforts to
     obtain coverage for him under any insurance policy now in force or
     hereinafter obtained during the term of this Agreement covering the other
     officers and directors of the Company against lawsuits. The Company shall
     pay all expenses including attorney`s fees, actually and necessarily
     incurred by the Executive in connection with the defense of such act, suit
     or proceeding, and in connection with any related appeal, including the
     cost of court settlements.

15.  Notices. All notices, requests, demands and other communications provided
     for by this Agreement shall be in writing and shall be deemed to have been
     given when mailed at any general or branch United States Post Office
     enclosed in a certified postpaid envelope, return receipt requested, and
     addressed to the address of the respective party stated below or to such
     changed address as the party may have fixed by notice:

     To the Company:       Gerald K. Carlson, Chief Executive Officer
                           Philipp Brothers Chemicals, Inc.
                           One Parker Plaza, 14th Floor
                           Fort Lee, NJ 07024

     Copy to:              Adrienne Messina, Vice President, Human Resources
                           Philipp Brothers Chemicals, Inc.
                           One Parker Plaza, 14th Floor

                           Fort Lee, NJ 07024

     To the Executive:     David McBeath
                           Carwinshoch
                           Carrick Hills
                           Ayr KA7 4LD, Scotland

     Any notice of change of address shall only be effective, however, when
received.

16.  Successors and assigns. This Agreement shall inure to the benefit of, and
     be binding upon, the Company, its successors and assigns, including,
     without limitation, any corporation which may acquire all or substantially
     all of the Company`s assets and business or into which the Company may be
     consolidated or merged, and the Executive, his heirs, executors,
     administrators and legal representatives. The executive may assign his
     right to payment, but not his obligations, under this Agreement.

17.  Applicable law. This Agreement shall be governed by the laws of the State
     of New York without giving effect to principles of conflicts of law.

                                       3
<PAGE>
18.  Other agreements. This Agreement supersedes all prior understandings and
     agreements between the parties. It may not be amended orally, but only by a
     writing signed by the parties hereto.

19.  Non-waiver. No delay or failure by either party in exercising any right
     under this Agreement, and no partial or single exercise of that right,
     shall constitute a waiver of that or any other right.

20.  Headings. Headings in this Agreement are for convenience only and shall not
     be used to interpret or construe its provisions.

21.  Counterparts. This Agreement may be executed in two or more counterparts,
     each of which shall be deemed an original but all of which together shall
     constitute one and the same instrument.

                                              Philipp Brothers Chemicals, Inc.

                                              Gerald K. Carlson
                                              Chief Executive Officer

                                              /s/ Gerald K. Carlson
                                              --------------------------------

                                              Jack C. Bendheim
                                              Chairman of the Board

                                              /s/ Jack C. Bendheim
                                              --------------------------------

                                              David McBeath

                                              /s/ David McBeath
                                              --------------------------------

                                       4
<PAGE>
                                    EXHIBIT A

1.   The Executive is a Board Member of the Roslin Institute and may continue to
     attend Board meetings and do such other things as are necessary and
     customary to fulfill his duties as a Board member.

2.   The Executive may continue his relationship with, and spend up to one (1)
     day per month on the affairs of, the Genesis Faraday Partnership Ltd.

3.   The Executive is a Board Member of Lifebio Limited and may continue to
     attend Board meetings and do such other things as are necessary and
     customary to fulfill his duties as a Board member. Lifebio Limited will not
     conduct trading activities during the term of this Agreement.

                                       5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00056-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00056-of-00352.parquet"}]]